Treatment of COVID-19
Coronavirus is a type of single-stranded RNA virus with a lipid bilayer called an envelope on the outside, and it looks like a corona under an electron microscope. It cannot self-regenerate, attaches to and enters human cells via ACE2 receptors, and proliferates within the human cells. There have been some coronaviral diseases such as SARS, MERS and "normal" human coronaviruses (HCoV) that cause common colds. The "new coronavirus" was named as SARS coronavirus-2 (SARS-CoV-2), and new coronavirus infectious disease caused by SARS-CoV-2 was named as COVID-19 short for "corona-virus disease discovered in 2019". SARS-CoV-2 infection spreads before the symptom onset, and prophylactic actions such as wearing masks and social or physical distancing are very important and critical. Treatment of COVID-19 is mainly performed by appropriately combining respiratory management, neutralizing antibody drugs, antiviral drugs, corticosteroids (dexamethasone, prednisolone, etc.), immunomodulators (baricitinib, tocilizumab), anticoagulants (heparin, etc.), and antibacterial drugs, and treatment of comorbidities is also performed in parallel.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:157 |
|---|---|
| Enthalten in: |
Nihon yakurigaku zasshi. Folia pharmacologica Japonica - 157(2022), 4 vom: 10., Seite 214-220 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Yatera, Kazuhiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 06.07.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1254/fpj.22019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343021919 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343021919 | ||
| 003 | DE-627 | ||
| 005 | 20231226015442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.1254/fpj.22019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343021919 | ||
| 035 | |a (NLM)35781447 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Yatera, Kazuhiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus is a type of single-stranded RNA virus with a lipid bilayer called an envelope on the outside, and it looks like a corona under an electron microscope. It cannot self-regenerate, attaches to and enters human cells via ACE2 receptors, and proliferates within the human cells. There have been some coronaviral diseases such as SARS, MERS and "normal" human coronaviruses (HCoV) that cause common colds. The "new coronavirus" was named as SARS coronavirus-2 (SARS-CoV-2), and new coronavirus infectious disease caused by SARS-CoV-2 was named as COVID-19 short for "corona-virus disease discovered in 2019". SARS-CoV-2 infection spreads before the symptom onset, and prophylactic actions such as wearing masks and social or physical distancing are very important and critical. Treatment of COVID-19 is mainly performed by appropriately combining respiratory management, neutralizing antibody drugs, antiviral drugs, corticosteroids (dexamethasone, prednisolone, etc.), immunomodulators (baricitinib, tocilizumab), anticoagulants (heparin, etc.), and antibacterial drugs, and treatment of comorbidities is also performed in parallel | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Nihon yakurigaku zasshi. Folia pharmacologica Japonica |d 1961 |g 157(2022), 4 vom: 10., Seite 214-220 |w (DE-627)NLM000003638 |x 0015-5691 |7 nnns |
| 773 | 1 | 8 | |g volume:157 |g year:2022 |g number:4 |g day:10 |g pages:214-220 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1254/fpj.22019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 157 |j 2022 |e 4 |b 10 |h 214-220 | ||